On 14 April 2026, Insilico Medicine announced the award of 3.71 million restricted share units (RSUs) to eligible employees under its Post-IPO RSU Scheme, in compliance with Rule 17.06A of the Hong Kong Listing Rules. The grant carries a nil purchase price and references the shares’ closing price of HK$60.35 on the grant date.
None of the 62 grantees is a director, chief executive, substantial shareholder or associate, and no individual exceeds the Listing Rules’ 1 % single-participant limit.
Award structure • Special Awards: 3.55 million RSUs allocated to 24 employees, vesting either (i) in eight equal quarterly tranches from the grant date or (ii) 50 % at the second employment anniversary (no earlier than 12 months after the grant date) with the balance vesting quarterly thereafter. • Regular Awards: 0.16 million RSUs distributed to 38 employees, vesting 33 % after one year and the remaining balance in equal quarterly tranches.
Vesting is subject to each recipient meeting or exceeding annual performance review criteria. Unvested units will lapse under specified circumstances, including breaches of confidentiality or competitive employment, as outlined in the company’s prospectus.
Plan capacity Following this grant, 24.16 million shares remain available for future awards under the company’s Post-IPO Equity Incentive Plans, of which 2.79 million are reserved for service providers.
Strategic intent Management states the RSU grant is designed to reward notable contributions to completed projects, align employee interests with long-term shareholder value and support retention of key talent.
Comments